Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma

J Infect Dis. 1994 Sep;170(3):659-62. doi: 10.1093/infdis/170.3.659.

Abstract

Fifteen Indian patients with relapsing or drug-refractory visceral leishmaniasis were retreated for 30 days with antimony plus interferon-gamma (IFN-gamma). All 15 had failure of an initial course of antimony and at least one additional course of antimony or pentamidine; 7 patients had failure of three or four prior courses of therapy. During the study, treatment was discontinued in 2 patients because of anemia and congestive heart failure in 1 and intractable vomiting in the other; both subsequently died. In the remaining 13 patients, IFN-gamma plus antimony treatment was associated with daily fever but no other adverse reactions. After 30 days of therapy, 9 (69%) of the 13 patients were apparently cured. Six months after treatment, all 9 were healthy, had parasite-free bone marrow aspirate smears, and were considered cured. None have relapsed during a mean follow-up of 15.9 +/- 1.7 months. These results support the use of antimony plus IFN-gamma as an immunochemotherapeutic alternative for kala-azar patients who have repeated failures of conventional treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Antimony Sodium Gluconate / therapeutic use*
  • Child
  • Combined Modality Therapy
  • Death
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • India
  • Interferon-gamma / therapeutic use*
  • Leishmaniasis, Visceral / therapy*
  • Male
  • Pentamidine / therapeutic use
  • Recombinant Proteins
  • Time Factors

Substances

  • Recombinant Proteins
  • Pentamidine
  • Interferon-gamma
  • Antimony Sodium Gluconate